Sandeep Sankineni1, Arvin K George2, Anna M Brown1, Soroush Rais-Bahrami2, Bradford J Wood3, Maria J Merino4, Peter A Pinto2, Peter L Choyke1, Baris Turkbey5,6. 1. Molecular Imaging Program, NCI, NIH, Bethesda, MD, USA. 2. Urologic Oncology Branch, NCI, NIH, Bethesda, MD, USA. 3. Center for Interventional Oncology, NCI and Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD, USA. 4. Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA. 5. Molecular Imaging Program, NCI, NIH, Bethesda, MD, USA. turkbeyi@mail.nih.gov. 6. Molecular Imaging Program, National Cancer Institute, 10 Center Dr, MSC 1182 Bldg 10, Room B3B85, Bethesda, MD, 20892-1088, USA. turkbeyi@mail.nih.gov.
Abstract
PURPOSE: The posterior subcapsular region of the prostate is often undersampled by transrectal ultrasound (TRUS)-guided biopsy. The close proximity of these lesions to the posterior capsular wall of the prostate makes them difficult to localize while increasing the need for early detection because of their increased risk for extracapsular extension. We retrospectively evaluated the multiparametric MRI (mpMRI) features of subcapsular prostate cancers to make radiologists more aware of this condition. MATERIALS AND METHODS: Between January 2010 and July 2014, all patients referred for 3T mpMRI and subsequent MR-US Fusion-guided biopsy (FgBx) and systematic 12-core sextant biopsy (SBx) under an IRB approved protocol, were reviewed, and imaging confirmed subcapsular prostate cancers were identified. Subcapsular lesions were defined as thin lesions that were just inside the prostate capsule. Matching patient demographics and clinical findings including age, PSA, PSA density, whole prostate volume, history of prostate cancer, Gleason score, and clinical management were tabulated. RESULTS: Of 992 eligible patients, 33 patients had subcapsular lesions in the prostate detected by mpMRI. Mean age, PSA, and prostate volume in this group were 63 years (range: 52-76 years), 8.4 ng/mL (range: 1.22-65.20), and 53 mL (range: 12-125 mL), respectively. The combination biopsy (SBx + FgBx) confirmed prostate cancer in 24 of 33 patients (72.7%) and in 9 patients the biopsy was negative. Of the 24 cancers, 19 were confirmed on both FgBx and conventional biopsy; however, 5 cancers were only detected on FgBx. In 4 of the 19 patients in which both biopsy methods were positive, the FgBx yielded a higher Gleason score. CONCLUSION: Subcapsular lesions on mpMRI are relatively infrequent but are usually malignant. Although the majority are confirmed on conventional 12-core biopsies, about 20% of these lesions require FgBx for diagnosis, and FgBx more accurately grades the lesions in another 20%. Thus, FgBx is of considerable benefit in confirming the diagnosis of subcapsular prostate cancer despite their proximity to the prostatic capsule.
PURPOSE: The posterior subcapsular region of the prostate is often undersampled by transrectal ultrasound (TRUS)-guided biopsy. The close proximity of these lesions to the posterior capsular wall of the prostate makes them difficult to localize while increasing the need for early detection because of their increased risk for extracapsular extension. We retrospectively evaluated the multiparametric MRI (mpMRI) features of subcapsular prostate cancers to make radiologists more aware of this condition. MATERIALS AND METHODS: Between January 2010 and July 2014, all patients referred for 3T mpMRI and subsequent MR-US Fusion-guided biopsy (FgBx) and systematic 12-core sextant biopsy (SBx) under an IRB approved protocol, were reviewed, and imaging confirmed subcapsular prostate cancers were identified. Subcapsular lesions were defined as thin lesions that were just inside the prostate capsule. Matching patient demographics and clinical findings including age, PSA, PSA density, whole prostate volume, history of prostate cancer, Gleason score, and clinical management were tabulated. RESULTS: Of 992 eligible patients, 33 patients had subcapsular lesions in the prostate detected by mpMRI. Mean age, PSA, and prostate volume in this group were 63 years (range: 52-76 years), 8.4 ng/mL (range: 1.22-65.20), and 53 mL (range: 12-125 mL), respectively. The combination biopsy (SBx + FgBx) confirmed prostate cancer in 24 of 33 patients (72.7%) and in 9 patients the biopsy was negative. Of the 24 cancers, 19 were confirmed on both FgBx and conventional biopsy; however, 5 cancers were only detected on FgBx. In 4 of the 19 patients in which both biopsy methods were positive, the FgBx yielded a higher Gleason score. CONCLUSION: Subcapsular lesions on mpMRI are relatively infrequent but are usually malignant. Although the majority are confirmed on conventional 12-core biopsies, about 20% of these lesions require FgBx for diagnosis, and FgBx more accurately grades the lesions in another 20%. Thus, FgBx is of considerable benefit in confirming the diagnosis of subcapsular prostate cancer despite their proximity to the prostatic capsule.
Authors: Baris Turkbey; Sheng Xu; Jochen Kruecker; Julia Locklin; Yuxi Pang; Marcelino Bernardo; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto Journal: BJU Int Date: 2011-01 Impact factor: 5.588
Authors: Annerleim Walton Diaz; Anthony N Hoang; Baris Turkbey; Cheng William Hong; Hong Truong; Todd Sterling; Soroush Rais-Bahrami; M Minhaj Siddiqui; Lambros Stamatakis; Srinivas Vourganti; Jeffrey Nix; Jennifer Logan; Colette Harris; Michael Weintraub; Celene Chua; Maria J Merino; Peter Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2013-06-18 Impact factor: 7.450
Authors: Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood Journal: J Urol Date: 2011-08-17 Impact factor: 7.450
Authors: Jeffrey W Nix; Baris Turkbey; Anthony Hoang; Dmitry Volkin; Nitin Yerram; Celene Chua; W Marston Linehan; Bradford Wood; Peter Choyke; Peter A Pinto Journal: BJU Int Date: 2012-10-04 Impact factor: 5.588
Authors: Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Urol Oncol Date: 2016-02-20 Impact factor: 3.498
Authors: Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto Journal: Future Oncol Date: 2016-07-12 Impact factor: 3.404
Authors: Akhil Muthigi; Arvin K George; Abhinav Sidana; Michael Kongnyuy; Richard Simon; Vanessa Moreno; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-08-28 Impact factor: 7.450
Authors: Akhil Muthigi; Abhinav Sidana; Arvin K George; Michael Kongnyuy; Nabeel Shakir; Meet Kadakia; Mahir Maruf; Thomas P Frye; Francesca Mertan; Daniel Su; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: Int Urol Nephrol Date: 2016-06-15 Impact factor: 2.370
Authors: Nabeel A Shakir; M Minhaj Siddiqui; Arvin K George; Michael Kongnyuy; Richard Ho; Michele Fascelli; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Urology Date: 2016-11-15 Impact factor: 2.649
Authors: Sena Tuncer; Sherif Mehralivand; Stephanie A Harmon; Thomas Sanford; G Thomas Brown; Lindsay S Rowe; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: Abdom Radiol (NY) Date: 2020-10
Authors: Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto Journal: Abdom Radiol (NY) Date: 2016-05
Authors: Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: CA Cancer J Clin Date: 2015-11-23 Impact factor: 508.702